- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01497002
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a (AML2004)
January 30, 2024 updated by: University of Leipzig
Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm.
Improvement of the treatment-results in elderly patients with acute myeloid leukemia through intensification of consolidation chemotherapy and/or allografting as consolidative immunotherapy
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Measuring EFS depending on induction therapy
Study Type
Interventional
Enrollment (Actual)
1222
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leipzig, Germany, 04103
- University of Leipzig, Hematology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients of both sexes with age > 60 years and newly diagnosed acute myeloid leukaemia as defined by new WHO classification
- written informed consent
Exclusion Criteria:
- pretreatment of leukemia
- no informed consent
- simultaneous inclusion in other studies
- mental disability
- contraindication for intensive chemotherapy
- AML FAB M3
- contraindication for allogeneic stem cell transplantation
- restriction of following organ functions:
- creatinine-clearance < 50 ml/min
- cardiac ejection fraction < 40 %
- severe pulmonary restriction
- bilirubin > 2x ULN; SGOT and SGPT > 4x ULN
- uncontrolled hypertension
- severe uncontrolled metabolism disturbance
- Karnofsky-performance-score < 70%
- hepatitis C
- other malignancy
- age of unrelated donor >70 years and age of related donor >75 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: standard arm
standard treatment arm
|
Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v.
24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5.
Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v.
3h-infusion a 12h day 1+3+5.
Other Names:
|
Experimental: OSHO - intensified consolidation
Intermediate dose AraC
|
Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v.
24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5.
Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v.
3h-infusion a 12h day 1+3+5.
Other Names:
|
Experimental: OSHO - allografting as consolidation
allogeneic stem cell Transplantation versus no transplantation
|
Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v.
3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c.
day 10.
Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v.
1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c.
day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event free survival
Time Frame: after 5 years
|
comparison of event free survival (OSHO arm versus Standard intergroup arm)
|
after 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: at 5 years
|
Overall survival
|
at 5 years
|
LFS
Time Frame: at 5 years
|
leukemia free survival
|
at 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dietger Niederwieser, Prof., University of Leipzig
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2005
Primary Completion (Actual)
July 18, 2018
Study Completion (Actual)
July 18, 2018
Study Registration Dates
First Submitted
December 21, 2011
First Submitted That Met QC Criteria
December 21, 2011
First Posted (Estimated)
December 22, 2011
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSHO#069
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukaemia
-
University of SydneyMelbourne Health; Royal Brisbane and Women's HospitalUnknown
-
Great Ormond Street Hospital for Children NHS Foundation...Wellcome TrustRecruitingRelapsed Acute Myeloid LeukaemiaUnited Kingdom
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedAcute Myeloid LeukaemiaFrance, United States, Australia
-
AstraZenecaCompletedAcute Myeloid LeukaemiaUnited Kingdom
-
AstraZenecaTerminatedAcute Myeloid LeukaemiaUnited States, Australia
-
Cellectis S.A.WithdrawnAcute Myeloid Leukaemia
-
Hospices Civils de LyonCompleted
-
medac GmbHCompleted
-
AstraZenecaCompletedAcute Myeloid LeukaemiaJapan
-
First Affiliated Hospital of Zhejiang UniversityCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.RecruitingMyeloid Malignancy | Relapsed/Refractory Acute Myeloid LeukaemiaChina
Clinical Trials on Cytarabine
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Jianxiang WangUnknownAcute Myeloid LeukemiaChina
-
Sunesis PharmaceuticalsCompletedAcute Myeloid LeukemiaUnited States, Canada, Spain, Belgium, Korea, Republic of, Australia, France, Germany, Poland, New Zealand, United Kingdom, Czechia, Austria, Hungary, Italy
-
Roswell Park Cancer InstituteJazz PharmaceuticalsRecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingRefractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent DiseaseUnited States
-
Fred Hutchinson Cancer CenterJazz PharmaceuticalsTerminatedAcute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene MutationsUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Institute of Hematology & Blood Diseases Hospital...Recruiting